Sibutramine: Sibutramine was withdrawn from most markets in 2010 due to increased risk of cardiovascular events (heart attack and stroke), particularly in patients with pre-existing cardiovascular disease. It is a centrally acting appetite suppressant that acts as a prodrug, metabolized to more pote
Related pages